Results 11 to 20 of about 28,817 (265)

A new staging system for hereditary transthyretin amyloidosis in the era of specific amyloidosis therapies

ESC Heart Failure
Objectives Currently, there are two prognosis staging systems validated for transthyretin amyloidosis (ATTR). We sought to develop a new staging system dedicated to hereditary transthyretin amyloidosis (ATTRv) patients on specific treatments. Methods and
Gabriela Neculae, Amira Zaroui, Robert Adam, Mounira Kharoubi, Benoit Funalot, Daniel Coriu, Ruxandra Jurcut, Thibaud Damy   +7 more
doaj   +2 more sources

Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis

eJHaem, 2022
The causal protein of amyloid light‐chain (AL) amyloidosis is a monoclonal immunoglobulin free light chain (mFLC), which must be quantified in the serum for patient diagnosis and monitoring.
Hajer Abroud, Asma Beldi‐Ferchiou, Vincent Audard, François Lemonnier, Fabien Le Bras, Karim Belhadj, Anissa Moktefi, Elsa Poullot, Khalil El Karoui, Jehan Dupuis, Alizée Maarek, Louise Roulin, Marie‐Hélène Delfau‐Larue, Silvia Oghina, Mounira Kharoubi, Mélanie Bézard, Amira Zaroui, Thibaud Damy, Valérie Molinier‐Frenkel   +18 more
doaj   +1 more source

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Biomedicines, 2022
Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen, Maaike Brons, Arco J. Teske, Marish I. F. J. Oerlemans   +3 more
doaj   +1 more source

Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021

Diagnostics, 2021
Cardiac amyloidosis is caused by the deposition of misfolded protein fibrils into the extracellular space of the heart. The diagnosis of cardiac amyloidosis remains challenging because of the heterogeneous manifestations of the disease.
Weijia Li, Dipan Uppal, Yu Chiang Wang, Xiaobo Xu, Damianos G. Kokkinidis, Mark I. Travin, James M. Tauras   +6 more
doaj   +1 more source

Role of cardiac MRI in the diagnosis of cardiac amyloidosis. Clinical cases

Клинический разбор в общей медицине, 2021
Purpose. The aim of this work is to show the capabilities of late gadolinium enhancement cardiac magnetic resonance imaging (MRI) in the diagnosis of a rare disease such as cardiac amyloidosis. Materials and methods.
Ekaterina A. Butorova , Olga V. Stukalova   +1 more
doaj   +1 more source

Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis

Annals of Noninvasive Electrocardiology, 2022
Background Cardiac amyloidosis is a protein misfolding disorder involving deposition of amyloid fibril proteins in the heart. The associated fibrosis of the conduction tissue results in conduction abnormalities and arrhythmias.
Perryn Lin Fei Ng, Yoke Ching Lim, Lauren Kay Mance Evangelista, Raymond Ching Chiew Wong, Ping Chai, Ching Hui Sia, Hoi Yin Loi, Tiong Cheng Yeo, Weiqin Lin   +8 more
doaj   +1 more source

Blood-based microRNA profiling in patients with cardiac amyloidosis. [PDF]

PLoS ONE, 2018
INTRODUCTION:Amyloidosis is caused by dysregulation of protein folding resulting in systemic or organ specific amyloid aggregation. When affecting the heart, amyloidosis can cause severe heart failure, which is associated with a high morbidity and ...
Anselm A Derda, Angelika Pfanne, Christian Bär, Katharina Schimmel, Peter J Kennel, Ke Xiao, P Christian Schulze, Johann Bauersachs, Thomas Thum   +8 more
doaj   +1 more source

Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Outcomes data in patients with cardiac amyloidosis after implantable cardioverter‐defibrillator (ICD) implantation are limited. We compared outcomes of patients with ICDs implanted for cardiac amyloidosis versus nonischemic cardiomyopathies ...
Angela Y. Higgins, Amarnath R. Annapureddy, Yongfei Wang, Karl E. Minges, Rachel Lampert, Lynda E. Rosenfeld, Daniel L. Jacoby, Jeptha P. Curtis, Edward J. Miller, James V. Freeman   +9 more
doaj   +1 more source

Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis

Methodist DeBakey Cardiovascular Journal, 2022
Cardiac amyloidosis is increasingly recognized as an underlying cause of left ventricular wall thickening, heart failure, and arrhythmia with variable clinical presentation.
Sajan S. Gill, Eric Fellin, Lisa Stampke, Yuanzi Zhao, Ahmad Masri   +4 more
doaj   +1 more source

Transthyretin cardiac amyloidosis in patients after TAVR: clinical and echocardiographic findings and long term survival

ESC Heart Failure, 2021
Aims The aim of this study was to examine the prevalence of amyloid transthyretin (ATTR) cardiac amyloidosis in patients 1–2 years after trans‐catheter aortic valve replacement (TAVR) and to assess their clinical and echocardiographic outcome and long ...
Sara Shimoni, Meital Zikri, Dan Haberman, Shay Livschitz, Sagi Tshori, Yacov Fabricant, Valery Meledin, Gera Gandelman, Sorel Goland, Jacob George   +9 more
doaj   +1 more source